BioLineRx Ltd. (NASDAQ:BLRX) Sees Large Drop in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 827,800 shares, a drop of 10.2% from the November 30th total of 921,900 shares. Based on an average daily trading volume, of 1,000,000 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BLRX. StockNews.com assumed coverage on BioLineRx in a report on Thursday, December 26th. They set a “hold” rating on the stock. HC Wainwright dropped their price target on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th.

Institutional Trading of BioLineRx

Several large investors have recently made changes to their positions in the company. CVI Holdings LLC bought a new stake in shares of BioLineRx in the 2nd quarter valued at about $462,000. Atria Investments Inc boosted its stake in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the last quarter. Finally, PVG Asset Management Corp acquired a new stake in shares of BioLineRx during the second quarter worth $70,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Price Performance

BLRX stock traded up $0.00 during midday trading on Tuesday, reaching $0.21. 1,393,354 shares of the company’s stock traded hands, compared to its average volume of 529,682. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The company has a market cap of $17.11 million, a price-to-earnings ratio of -0.97 and a beta of 1.39. BioLineRx has a 1-year low of $0.19 and a 1-year high of $1.59. The company has a 50-day simple moving average of $0.33 and a two-hundred day simple moving average of $0.53.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.